Fibrates and TZDs have both shown beneficial cardiovascular effects in clinical trials3,10,11, which together with their complementary action on glucose and lipid metabolism spurred the development of PPARɑ/ɣ dual agonists (Glitazars) for the treatment of type 2 diabetes (T2D) and dyslipidaemia1. This evidence concerns the gene PPARA and type 2 diabetes mellitus.